HSR waiting period expires for Bristol-Myers Squibb’s tender offer for Inhibitex
Bristol-Myers Squibb has announced that the Hart-Scott-Rodino waiting period has expired for its cash tender offer to purchase all outstanding shares of common stock of Inhibitex. Inhibitex is a drug maker that develops drugs for treating hepatitis C. The tender offer will expire at midnight EST on February 10.
Featured News
Tech Policy and Regulation Weekly Roundup
Jan 23, 2026 by
CPI
Perkins Coie Adds Former DOJ Antitrust Leader as Partner in Washington
Jan 22, 2026 by
CPI
Ryanair Boss Dismisses Musk’s Buyout as Starlink Feud Escalates
Jan 22, 2026 by
CPI
Paramount Extends Warner Bros Bid as Netflix Rivalry Heats Up
Jan 22, 2026 by
CPI
South Korea Breaks New Ground With Landmark AI Law
Jan 22, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Recidivism
Jan 21, 2026 by
CPI
Recidivism, Multiple Offending, and Serial Offending in Antitrust
Jan 21, 2026 by
Gregory Werden
Antitrust Recidivism: Why Repeat Cases Appear, and Why True Reoffending Is Rare in the United States
Jan 21, 2026 by
Lisa M. Phelan, Megan S. Golden, Adrienne Irmer & Nina Worth
99 Antitrust Problems – Is Recidivism One?
Jan 21, 2026 by
Brian A. Ratner & Kartik S. Madiraju
Holding A Cat by the Tail: A View of Cartel Recidivism in U.S. Antitrust Enforcement
Jan 21, 2026 by
Mark Rosman & KaDee L. Ru